国际妇产科联合会（FIGO）于2023年修订了子宫内膜癌分期系统。在本研究中，我们旨在使用FIGO2008、无分子分类的FIGO2023（FIGO2023）和有分子分类的FIGO2023确定子宫内膜癌的分期转变和预后。分类 (FIGO2023m)。作为 Project HOPE 队列研究的一部分，纳入了 83 名诊断患有子宫内膜癌的患者，他们接受了手术和下一代测序 (NGS) 分子分析。每个病例根据FIGO2008和FIGO2023标准进行分期，我们评估分期和疾病特异性生存（DSS）的变化。采用基于NGS的分子分型对FIGO2023m进行评估，并评估与免疫组化标志物分析的一致率。从FIGO2008过渡到FIGO2023导致18例病例重新分期。相反，从FIGO2008过渡到FIGO2023m导致15个病例重新分期。 FigO2023与FIGO2023m分期的一致性为96.4%。对于FIGO2023m，I 期的 5 年 DSS 为 97.6%（95% 置信区间 [CI] 83.9-99.7），II 期为 83.3%（95% CI 56.8-94.3），III 期为 100%（95% CI） NA)，IV 期为 25.0% (95% CI 0.9-66.5)。两例病例因简化替代标志物分析与NGS评估不一致而导致疾病分期出现差异。分期系统从FIGO2008修订为FIGO2023和FIGO2023m导致数例病例重新分期，I期和II期之间发生显着变化。©作者 2024。牛津大学出版社出版。版权所有。如需权限，请发送电子邮件至：journals.permissions@oup.com。

The International Federation of Gynecology and Obstetrics (FIGO) revised the staging system of endometrial cancer in 2023. In this study, we aimed to determine stage transitions and prognosis of endometrial cancer using FIGO2008, FIGO2023 without molecular classification (FIGO2023), and FIGO2023 with molecular classification (FIGO2023m).Eighty-three patients diagnosed with endometrial cancer who underwent surgery and next-generation sequencing (NGS) molecular profiling as part of the Project HOPE cohort study were enrolled. Each case was staged according to the FIGO2008 and FIGO2023 criteria, and we evaluated changes in stage and disease-specific survival (DSS). Molecular classification based on NGS was performed to evaluate FIGO2023m, and the concordance rate with immunohistochemical marker analysis was assessed.Transitioning from FIGO2008 to FIGO2023 resulted in the restaging of 18 cases. Conversely, transitioning from FIGO2008 to FIGO2023m led to the restaging of 15 cases. The concordance rate between FIGO2023 and FIGO2023m staging was 96.4%. With FIGO2023m, the 5-year DSS was 97.6% for stage I (95% confidence interval [CI] 83.9-99.7), 83.3% for stage II (95% CI 56.8-94.3), 100% for stage III (95% CI NA), and 25.0% for stage IV (95% CI 0.9-66.5). Discrepancies in disease staging due to discordance between simplified surrogate marker analysis and NGS evaluation occurred in two cases.The revision of the staging system from FIGO2008 to FIGO2023 and FIGO2023m resulted in the restaging of several cases, with significant changes between stages I and II.© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.